|Articles|April 13, 2019

Urinary HPV Testing May Be an Alternative to Pap Smear

Investigators on the CapU3 study concluded that urinary HPV testing may be a good alternative to Pap smear for some women.

The current standard of cervical cancer screening in France is cytological examination of a Pap smear, but collection is considered invasive and burdensome for some women. Investigators with University Hospital Center of Angers wanted to determine whether a urine test for human papillomavirus (HPV) would increase compliance rates.

The research team presented findings from the CapU3 study in an oral session at the European Congress for Clinical Microbiology and Infectious Diseases (ECCMID 2019).

In collaboration with the cancer screening coordination center of Pays de la Loire, investigators offered urinary HPV testing to 13,535 women aged 35 to 65 who had not had a Pap smear in the last 7 years.

The urinary test for HPV involves a real-time polymerase chain reaction technique (Anyplex II HPV28 Detection) that can detect 28 genotypes (19 high-risk HPV and 9 low-risk HPV). Patients who receive a positive test are encouraged to follow up with a Pap smear, while women who test negative are advised to undergo a Pap smear within 1 year.

After accounting for exclusion, 1781 samples were ultimately analyzed in the trial (participation rate 14.5%). A total of 1576 were negative for at least 1 high-risk HPV strain, while 183 samples tested positive. Twenty-two samples returned invalid results. Among the patients with abnormal follow-up cervical smears, 4 cervical intraepithelial neoplasia grade 3, and 6 grade 1 lesions were detected after colposcopies with biopsies.

Investigators concluded that urinary HPV testing may be a good alternative to undergoing a Pap smear.

“Because home HPV urinary testing is non-invasive and do[es] not require medical attention, this method may be an alternative for women who are reluctant to use Pap smear,” the investigators wrote. “Furthermore, 72.0% of the HPV-positive women included in the CapU3 study benefited from a Pap smear collected by a clinician during follow-up. So, the urinary HPV test could be an alternative to the usual screening by cervical smear thus extending screening coverage in our department.”

The study, “Urinary HPV DNA testing as a tool for cervical cancer screening in France: CapU3 study,” was presented in an oral session on Saturday, April 13, 2019, at ECCMID 2019 in Amsterdam, the Netherlands.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.